Shape of the Nations survey and attitudes to cardiometabolic risk

Current Medical Research and Opinion

Volumn 23, Issue 1, 2007, Pages 25-28

  Wierzbicki, Anthony S ^a   Ganotakis, Emmanuel S ^b,c   Mikhailidis, Dimitri P ^c  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CRETE   (Greece)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL;

BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIET SUPPLEMENTATION; FAMILY HISTORY; HEALTH SURVEY; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OBESITY; PRIMARY MEDICAL CARE; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ATTITUDE; BODY COMPOSITION; BODY MASS INDEX; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HEALTH SURVEYS; HUMANS; INTRA-ABDOMINAL FAT; METABOLIC SYNDROME X; OBESITY; RISK FACTORS;

EID: 33846706281     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X162638     Document Type: Note

References (45)

1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782-7
2. James PT, Rigby N, Leach R. The obesity epidemic, metabolic syndrome and future prevention strategies. Eur J Cardiovasc Prev Rehabil 2004;11:3-8
3. Smith SC, Haslam D. Abdominal obesity, waist circumference and cardiometabolic risk: awareness among primary care physicians, the general population and patients at risk - the Shape of the Nations survey. Curr Med Res Opin 2007;23:29-47
4. Folsom AR, Kushi LH, Anderson KE, Mink PJ, et al. Associations of general and abdominal obesity with multiple health outcomes in older women: the Iowa Women's Health Study. Arch Intern Med 2000;160:2117-28
5. Kragelund C, Omland T. A farewell to body-mass index? Lancet 2005;366:1589-91
6. Dagenais GR, Yi Q, Mann JF, Bosch J, et al. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J 2005;149:54-60
7. Yusuf S, Hawken S, Ounpuu S, Bautista L, et al. Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study. Lancet 2005;366:1640-9
8. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
9. Tan CE, Ma S, Wai D, Chew SK, et al. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care 2004;27:1182-6
10. Wierzbicki AS, Nishtar S, Lumb PJ, Lambert-Hammill M, et al. Metabolic syndrome and risk of coronary heart disease in a Pakistani cohort. Heart 2005;91:1003-7
11. Snehalatha C, Viswanathan V, Ramachandran A. Cutoff values for normal anthropometric variables in Asian Indian adults. Diabetes Care 2003;26:1380-4
12. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 2005;366:1059-62
13. Antipatis VJ, Kumanyika S, Jeffery RW, Morabia A, et al. Confidence of health professionals in public health approaches to obesity prevention. Int J Obes Relat Metab Disord 1999;23:1004-6
14. Li Z, Maglione M, Tu W, Mojica W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005;142:532-46
15. James WP, Astrup A, Finer N, Hilsted J, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000;356:2119-25
16. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-61
17. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-97
18. Hirschel B. Effect of rimonabant on weight reduction and cardiovascular risk. Lancet 2005;366:369-70
19. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295:761-75
20. Holt R. Orlistat reduces features of the metabolic syndrome: the XENDOS study. Diabetes Obes Metab 2003;5:356
21. Maggard MA, Shugarman LR, Suttorp M, Maglione M, et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med 2005;142:547-59
22. Loos RJ, Bouchard C. Obesity - is it a genetic disorder? J Intern Med 2003;254:401-25
23. Wierzbicki AS, Mikhailidis DP. Beyond LDL-C-the importance of raising HDL-C. Curr Med Res Opin 2002;18:36-44
24. Burchfiel CM, Laws A, Benfante R, Goldberg RJ, et al. Combined effects of HDL cholesterol, triglyceride, and total cholesterol concentrations on 18-year risk of atherosclerotic disease. Circulation 1995;92:1430-6
25. Alberti KG. Impaired glucose tolerance: what are the clinical implications? Diabetes Res Clin Pract 1998;40(Suppl):S3-8
26. Chapman MJ, Assmann G, Fruchart JC, Shepherd J, et al. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid - a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004;20:1253-68
27. Sacks FM. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 2002;90:139-43
28. Wierzbicki AS. Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention? Curr Med Res Opin 2005;21:299-306
29. Rizos E, Mikhailidis DP. Are high-density lipoprotein and triglyceride levels important in secondary prevention: impressions from the BIP and VA-HIT trials. Int J Cardiol 2002;82:199-207
30. Nishtar S, Wierzbicki AS, Lumb PJ, Lambert-Hammill M, et al. HDL-cholesterol and waist-hip ratio predict risk of coronary heart disease in Pakistan. Curr Med Res Opin 2004;20:55-62
31. Chambers JC, Eda S, Bassett P, Karim Y, et al. C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation 2001;104:145-50
32. Simmons D, Shaw LM, Scott DJ, Kenealy T, et al. Diabetic nephropathy and microalbuminuria in the community. The South Auckland Diabetes Survey. Diabetes Care 1994;17:1404-10
33. Zimmet PZ, McCarty DJ, de Court. The global epidemiology of non-insulin-dependent diabetes mellitus and the metabolic syndrome. J Diabetes Complications 1997;11:60-8
34. Abdul-Ghani MA, Sabbah M, Muati B, Dakwar N, et al. High frequency of pre-diabetes, undiagnosed diabetes and metabolic syndrome among overweight Arabs in Israel. Isr Med Assoc J 2005;7:143-7
35. Onat A. Risk factors and cardiovascular disease in Turkey. Atherosclerosis 2001;156:1-10
36. Hergenc G, Schulte H, Assmann G, von EA. Associations of obesity markers, insulin, and sex hormones with HDL-cholesterol levels in Turkish and German individuals. Atherosclerosis 1999;145:147-56
37. Athyros VG, Ganotakis ES, Bathianaki M, Monedas I, et al. Awareness, treatment and control of the metabolic syndrome and its components: a multicentre Greek study. Hellenic J Cardiol 2005;46:380-6
38. Sattar N, Gaw A, Scherbakova O, Ford I, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-9
39. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52:1210-4
40. Zimmet P, Boyko EJ, Collier GR, de Court. Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players. Ann N Y Acad Sci 1999;892:25-44
41. Sattar N, Gaw A, Scherbakova O, Ford I, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-9
42. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
43. Liberopoulos EN, Tsouli S, Mikhailidis DP, Elisaf MS. Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Curr Drug Targets 2006;7:211-28
44. Athyros VG, Ganotakis ES, Elisaf M, Mikhailidis DP. The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin 2005;21:1157-9
45. Hunt KJ, Resendez RG, Williams K, Haffher SM, et al. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004;110:1251-7